As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:
16 Analysts have issued a Halozyme Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1,243 1,243 |
31%
31%
|
|
| Gross Profit | 1,051 1,051 |
35%
35%
|
|
| EBITDA | 808 808 |
48%
48%
|
|
| EBIT (Operating Income) EBIT | 737 737 |
55%
55%
|
|
| Net Profit | 595 595 |
52%
52%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Helen Torley |
| Employees | 350 |
| Founded | 1998 |
| Website | www.halozyme.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


